In recent trading session, Cytokinetics, Incorporated (NASDAQ:CYTK) saw 1,529,807 shares changing hands with its beta currently measuring 1.43. Company’s recent per share price level of $26.22 trading at $0.1 or 0.46% at recent trade assigns it a market valuation of $1.56 Billion. That current trading price of CYTK’s stock is at a discount of -7.7% from its 52-week high price of $28.24 and is indicating a premium of 70.52% from its 52-week low price of $7.73. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 616.1 Million shares which gives us an average trading volume of 837.5 Million if we extend that period to 3-months.

For Cytokinetics, Incorporated (CYTK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 8 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.56 in the current quarter.

Cytokinetics, Incorporated (NASDAQ:CYTK) trade information

Upright in the green today for gaining 1.57%, in the last five days CYTK remained trading in the green while hitting it’s week-highest on Friday, Jul 10 when the stock touched $28.25- price level, adding 6.23% to its value on the day. Cytokinetics, Incorporated’s shares saw a change of 149.67% in year-to-date performance and have moved 6.69% in past 5-day. Cytokinetics, Incorporated (NASDAQ:CYTK) showed a performance of 22.02% in past 30-days. Number of shares sold short was 7.72 Million shares which calculate 0.01 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $31.75 to the stock, which implies a rise of 21.09% to its current value. Analysts have been projecting $23 as a low price target for the stock while placing it at a high target of $39. It follows that stock’s current price would jump +48.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -12.28% for stock’s current value.

Cytokinetics, Incorporated (CYTK) estimates and forecasts

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $4.69 Million for the same. And 5 analysts are in estimates of company making revenue of $4.49 Million in the next quarter that will end in September 01, 2020. Company posted $6.92 Million and $6.05 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -32.2% while estimating it to be -25.8% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -38.8% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -8.2% while estimates for its earnings growth in next 5 years are of 15%